Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Nevro surpasses Q1 expectations, eyes long-term growth in SCS market

Nevro's Q1 performance exceeded guidance, driven by global revenue growth and the successful launch of the HFX iQ System in the U.S. The company is well-positioned to capitalize on the long-term growth potential of the spinal cord stim market, while also navigating potential pricing challenges and strategic considerations.

Nevro reports 4% revenue growth but issues cautious 2023 guidance

Nevro's Q2 performance showed revenue growth and strategic hires, but challenges in market dynamics and competitive pressures led to revised guidance for 2023. The company is focused on professionalizing the organization, launching innovative products, and leveraging opportunities in PDN sales and HFX coach utilization to drive future growth.

Nevro reports 3% revenue growth in Q3, optimistic about future

Nevro's Q3 performance showed revenue growth and strong potential in the SCS and PDN spaces. However, challenges in gross margin and EBITDA losses require attention. The company remains optimistic about future growth and profitability.

NVRO reports Q4 revenue growth and strategic focus for 2024

NVRO's Q4 performance showed revenue growth and positive adjusted EBITDA, driven by PDN sales. The company's strategic pillars focus on commercial execution, market expansion, and cost efficiencies. Challenges lie in achieving profitability in 2024 amidst operating expenses, while opportunities exist in new product development and market penetration.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Wall Street cheers after the company announced a surprise change in the corner office. Here's what investors need to know.

Here's Why Nevro Is Skyrocketing Today

Nevro's (NVRO) solid domestic and international performance aids Q4 results.

Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat

News for Nevro Stock (NVRO)